BMS-986453 : A Next-Generation Dual-Target CAR-T Attacking BCMA + GPRC5D in Myeloma | #EHA2026

Could targeting two myeloma markers with one CAR-T cell help overcome treatment resistance?

At EHA 2026, researchers presented updates on BMS-986453, an investigational dual-targeting CAR-T therapy designed to recognize both BCMA and GPRC5D in multiple myeloma.

Current CAR-T therapies have transformed myeloma treatment, but relapse can occur when myeloma cells escape by changing or losing their target. By combining two important myeloma targets — BCMA, a well-established CAR-T target, and GPRC5D, a newer myeloma target — this next-generation approach aims to give engineered T cells a broader ability to find and attack myeloma cells.

In this video, learn about the science behind dual-target CAR-T, the “loop tandem” CAR design strategy, and why targeting multiple antigens may represent the future of cellular therapy in multiple myeloma.

Presented at EHA 2026.

If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/628617/src=htu

For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity
Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!

Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general
Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.